IP Library Granted Patent US 9,416,165
Granted Patent B2
US 9,416,165 · App. 12/739,639 · Granted Aug 16, 2016

Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,416,165
App. No.
12/739,639
Granted
Aug 16, 2016
Kind
B2
Abstract

The application relates to methods of treating a chronic viral infection, such as HIV (Human Immunodeficiency Virus), by modulating Tim-3 activity, whereby blocking the action of Tim-3 on a T cell enhances the immunity to the virus.

Claims (6)

1. A method of inhibiting a chronic viral infection in a subject in need thereof comprising administering an effective amount of an inhibitor of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3); wherein the inhibitor is a soluble form of Tim-3 comprising SEQ ID NO: 2 or 6.

2. The method of claim 1 wherein the viral infection is a human immunodeficiency virus (HIV) infection or hepatitis C virus (HCV) infection.

3. The method of claim 1 , further comprising administering an effective amount of an antigen expressed by a virus that causes the chronic infection.

4. The method of claim 3 , wherein the virus is human immunodeficiency virus type 1 (HIV-1) or hepatitis C virus (HCV).

5. A method for improving the function of functionally impaired Th1 CD4+ helper T cells or cytotoxic killer CD8+ T cells in a subject in need thereof comprising administering an effective amount of an inhibitor of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3); wherein the inhibitor is a soluble form of Tim-3 comprising SEQ ID NO: 2 or 6; and wherein the improved function is determined by increased production of IFN-gamma and INF-alpha and/or by degranulation.

6. The method of claim 5 , wherein the improved function is determined by increased production of IFN-gamma and TNF-alpha.

Assignments (7)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER Recorded Jan 28, 2020
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE LLC
Reel/Frame 051646/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2020
From: JONES, RICHARD BRAD; OSTROWSKI, MARIO; RINI, JAMES
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 051646/0762 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2016
From: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
To: JONES, RICHARD B.; OSTROWSKI, MARIO; RINI, JAMES
Reel/Frame 039099/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: JONES, RICHARD BRADLEY; OSTROWSKI, MARIO ANTHONY
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 030533/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: RINI, JAMES
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 030534/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2013
From: NDHLOVU, LISHOMWA CHAKANGA; NIXON, DOUGLAS F.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 030539/0100 →